About / Our clinical research
Leading the science of advanced therapy care beyond the hospital
Peer-reviewed journal articles, reviews, and conference abstracts from our work with leading cancer centers, health systems, and pharma and biotech companies.
60
peer-reviewed papers and abstracts
89%
of patients who began bispecific step-up dosing outpatient reached full dose (MSK)
7 hrs
earlier CRS recognition than standard inpatient nursing care (Mount Sinai)
15+
global clinical trials supported
Research focus areas
Building the evidence base for safe advanced therapy delivery outside the hospital
Toxicity detection
Developing and validating algorithms for earlier CRS detection, studying the physiological signs that precede symptoms, and validating virtual ICANS assessments, including remote ICE presentation and escalation criteria.
Program and protocol design
Testing the clinical pathways, escalation rules, and monitoring windows that outpatient programs run on, and measuring their impact on provider experience, from workload and overnight calls to confidence sending patients home.
Ambulatory safety
Building the evidence for outpatient CAR-T and bispecific delivery, including eligibility criteria and monitoring protocols.
Outcomes research
Characterizing real-world outcomes, including response rates, adverse events, hospitalizations, and quality of life.
Health economics
Quantifying the cost savings of ambulatory delivery and supporting value-based contracting.
Digital biomarkers
Developing physiological signatures for early adverse event detection from continuous biometric data.
Research partnerships
How we work with research partners
Our internal research team works with your program to turn its data into evidence for leadership, payers, and the field.
From idea to publication
- Joint publications and abstracts
- IRB protocol development and support
- Data collection, storage, and analysis
- Outcomes and quality tracking
- Commercial payer evidence development
Highlighted research
Highlights from our research
Studies with our partners on the quality, experience, and operations of outpatient CAR-T, bispecific, and other advanced therapy delivery.
Paper
Rajeeve S, Wilkes M, Zahradka N, et al. JCI Insight, 2026 (11(12): e203988)
Paper
Medberry C, et al. J Med Internet Res, 2025 (27: e71956)
Abstract
Battiwalla M, et al. ASTCT Tandem Meetings, 2026
Abstract
Rajeeve S, et al. Blood, 2025 (146 Suppl 1: 2751)
Abstract
Remote Patient Monitoring for 15 Vs. 30 Days in Outpatient CAR-T across a Large Health System ↗
Cox T, et al. Transplantation and Cellular Therapy, 2025 (31(2): S223–S224)
Paper
Outpatient Administration of CAR-T Therapy Using Remote Patient Monitoring ↗
Majhail NS, et al. JCO Oncology Practice, 2025 (OP2500062)
Abstract
Cox T, et al. Blood, 2024 (144 Suppl 1: 2300)
Abstract
Cox T, et al. Transplantation and Cellular Therapy, 2024 (30(2): S216–S217)
Abstract
Cotarla I, et al. Int J Radiat Oncol Biol Phys, 2024 (118(1): e8–e9)
Abstract
Outpatient blinatumomab with digital monitoring in MRD+ B-ALL in a phase 4 study ↗
Pardee T, et al. J Clin Oncol, 2024 (42: 6544)
Abstract
Rajeeve S, et al. Blood, 2023 (142: S1007)
Abstract
Rajeeve S, et al. Clinical Lymphoma Myeloma and Leukemia, 2023 (23: S58)
Abstract
Early detection of CRS after CAR-T using wearable monitoring devices: preliminary results in RRMM ↗
Rajeeve S, et al. J Clin Oncol, 2023 (41:16_suppl, e13626)
Abstract
Cotarla I, et al. J Clin Oncol, 2023 (41:16_suppl, e20562)
Abstract
Promoting digital health equity through remote patient monitoring: a feasibility study ↗
Kessler A, et al. J Clin Oncol, 2022 (40:28_suppl, 441)
Abstract
A feasibility study of remote patient monitoring among vulnerable patients with cancer ↗
Kessler A, et al. J Clin Oncol, 2022 (40:16_suppl, e13652)
Trial protocol
A Phase 4 Study to Evaluate Outpatient Blinatumomab in Patients With MRD Positivity of BCP-ALL ↗
Khan S, et al. J Clin Oncol, 2021 (39:15_suppl, TPS7051)
A shared research framework
One set of outcome measures across every program
Every program we support captures the same six outcome domains. That shared standard is what lets our research team pool data across sites and therapies, compare models fairly, and publish findings that hold beyond a single center.
Accessibility
Impact of expanded inclusion criteria: distance, caregiver requirements, and reduced patient financial toxicity
Clinical effectiveness and safety
Clinical outcomes, safety metrics and rates of adverse events, and resource utilization
Patient and caregiver experience
Experience measures, patient-reported outcomes, and net promoter score
Shift rate
Percent of advanced therapy cases successfully delivered as outpatient
Utilization
Inpatient bed days avoided, ED visits, admissions and time to hospitalization, and the financial impact of each
Operational efficiency
Operational metrics and staff experience
Want to talk about research?
Tell us what you're working on, and we'll find the right way to work together.